A joint program between Bionomics Ltd., of Thebarton, Australia, and the Co-operative Research Centre for Cancer Therapeutics reached a proof-of-concept milestone for Ctx-0357927, an inhibitor of vascular growth factor receptor 3

The FDA approved Tarceva (erlotinib) tablets for first-line treatment of metastatic non-small-cell lung cancer characterized by tumors with epidermal growth factor receptor-activating mutations

Ltd., said Harvard Medical School presented data at the Association for Research in Vision and Ophthalmology conference in Seattle showing a major link between vascular endothelial growth factor (VEGF)-C levels and age-related macular degeneration (AMD) and that assessment of Opthea's drug development candidate, VGX-300 (a soluble form of VEGF receptor-3 that blocks VEGF-C and VEGF-D) in animal models of wet AMD confirmed its potential as a new therapy for the disease

Cardium Therapeutics Inc., of San Diego, said the April 2013 issue of Molecular Therapy published a paper, titled "Mechanistic, Technical, and Clinical Perspectives in Therapeutic Stimulation of Coronary Collateral Development by Angiogenic Growth Factors

In a second program, a class of compounds that target two different growth factor signaling pathways in oncology is in the late lead optimization phase

In a second program, a class of compounds that target two different growth factor signaling pathways in oncology is in the late lead optimization phase

The licensed technology uses one of BioTime's HyStem hydrogels to deliver locally released growth factors to improve recovery from stroke...Preclinical studies have demonstrated that the localized delivery of growth factors such as brain-derived neurotrophic factor results in a statistically significant improvement in post-stroke motor function in a murine model of ischemic stroke

Minerva Biotechnologies Corp., of Waltham, Mass., said its scientists converted established human stem cells to the naïve state and maintained them there indefinitely by culturing the cells in the dimeric form of a natural but newly discovered human growth factor, NM23-H1

The patent portfolio includes 12 patent families with claims relating to important biological targets, including vascular endothelial growth factor, hypoxia-inducible factor 1-alpha, intracellular adhesion molecule 1, angiopoietin 2 and complement component 3

The publication described a new mechanism of action, which showed placental growth factor (PlGF) plays a vital role in the brain and its expression is required for the growth and spread of medulloblastoma

The publication described a new mechanism of action, which showed placental growth factor (PlGF) plays a vital role in the brain and that its expression is required for the growth and spread of medulloblastoma...TikoMed's product is designed to enhance the outcome of the treatment by improving the survival of transplanted cells by inhibiting a destructive immunological reaction and through stimulation of growth factors

The drug strongly induced production of insulin-like growth factor, a principal mediator of growth hormone activity...Dompe Group, of Milan, Italy, said the first patient has been enrolled in a Phase I/II REPARO study evaluating the ophthalmological use of a topical solution of recombinant human nerve growth factor (rhNGF) for the treatment of moderate to severe neurotrophic keratitis (NK

Acorda Therapeutics Inc., of Hawthorne, New York, reported data showing that glial growth factor 2 enhances recovery of sensorimotor function in a stroke model

to test AXL1717, an oral small-molecule insulin-like growth factor 1 receptor inhibitor, in patients with malignant astrocytomas, a type of brain tumor

Astellas Pharma Inc., of Tokyo, said the FDA accepted for filing a supplemental new drug application for Tarceva (erlotinib) for first-line use in patients with locally advanced or metastatic non-small-cell lung cancer whose tumors have epidermal growth factor receptor (EGFR)-activating mutations...Afatinib is under review for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer with an epidermal growth factor receptor mutation as detected by an FDA-approved test

Astellas Pharma Inc., of Tokyo, said the FDA accepted for filing a supplemental new drug application for Tarceva (erlotinib) for first-line use in patients with locally advanced or metastatic non-small-cell lung cancer whose tumors have epidermal growth factor receptor (EGFR)-activating mutations

Afatinib is under review for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer with an epidermal growth factor receptor mutation as detected by an FDA-approved test

Ironwood plans to initiate Phase I studies in healthy volunteers to assess the pharmacokinetics of IW-2143...Immune Pharmaceuticals Ltd., of Herzlyia-Pituach, Israel, and EpiCept Corp., of Tarrytown, N.Y., entered a merger agreement, anticipated to close in the first quarter of 2013, that will create a combined company – Immune Pharmaceuticals Inc. – focused on developing antibody therapeutics and other targeted drugs

Theliatinib is an inhibitor of epidermal growth factor receptor (EGFR) that has shown strong antitumor activity against EGFR wild-type tumors in preclinical studies